24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
DreaMed
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:17
Amdocs' four-year restructuring drive has cost $436 million and cut around 7,500 jobs
20:47
Replacing Jensen Huang could force Nvidia to reinvent the way it operates
16:11
Jensen Huang steps down as Nvidia CEO, leaving the AI industry without its leading champion
15:11
Saudi Arabia's sports spending spree is over. Its global ambitions are not
More stories
Buzz
Most popular
Daily
Weekly
1
Palo Alto’s $25 billion CyberArk deal was worth $21 billion at closing. The shares are now worth $37 billion
2
CyberArk layoffs cost Palo Alto an estimated $60 million
3
CrowdStrike's business chief: "We're long on Israel and we're not going anywhere"
4
Elligint Health acquires Israeli startup Laguna in deal estimated to be worth tens of millions of dollars
5
The race to replace Jensen Huang: Nvidia's potential successors include an Israeli executive
More news
DreaMed
3 stories about DreaMed
Israeli startup DreaMed gets FDA approval for app that adjusts insulin doses for Type 2 diabetes
28.09.26
|
Meir Orbach
MODI analyzes glucose and treatment data to provide personalized dosage recommendations between doctor visits without requiring approval for each adjustment.
DreaMed secures $3M and strategic deals amid CEO's reserve IDF duty
19.08.24
|
CTech
The AI solution developed by DreaMed is designed to provide treatment recommendations to millions of people with diabetes who do not have access to endocrinologists.
Did you know code can kill?
24.05.22
|
Eran Agmon
The conversation on system bugs can start with user experience and data but can very quickly reach human life, writes Eran Agmon, Chief Product Officer at DreaMed